ASCB

bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post

Retrieved on: 
Tuesday, November 28, 2023
Research, Medical Devices, Surgery, Genetics, Biotechnology, Radiology, Pharmaceutical, Health, Science, Oncology, BIAF, ASCB, Cell biology, Student, Cell, European, EMBO, European Molecular Biology Organization, Society, Government, Education, Pharmaceutical industry, Management

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB).

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer and lung disease, today announced that David Elzi, Ph.D., bioAffinity Technologies Vice President of Research, has been named to the Membership Committee of the American Society for Cell Biology (ASCB).
  • First organized in 1960, ASCB is an international organization of cell biologists dedicated to advancing scientific discovery, advocating sound research policies, improving education, promoting professional development and increasing diversity in the scientific workforce.
  • The Membership Committee is responsible for implementing programs and services to meet the needs of the ASCB’s membership and support its mission and strategic plan, including recruiting new members and retaining current members.
  • Aimed at students, post-docs and research scientists, the roundtable will be held Dec. 3, 2023, at 1:15 p.m.

Newtown's Apple to Highly Saturated Global Molecular Market, TIANGEN TGuide S16 Automated Nucleic Acid Extractor Showcased at Cell Bio 2022

Retrieved on: 
Tuesday, December 6, 2022
Duke University, Cell biology, Thomas D. Pollard, Society, Research, ASCB, Cell, S16, University of California, Molecular biology, Wizard Product Review, EMBO, University, GM, European Molecular Biology Organization, Harvard Medical School, RNA, Fine chemical, A4

Eye-catching as it is, the smart automated extractor hit the great potential need of global research scientists about nucleic acid purification and received more than 50 direct trial requests.

Key Points: 
  • Eye-catching as it is, the smart automated extractor hit the great potential need of global research scientists about nucleic acid purification and received more than 50 direct trial requests.
  • For molecular and cell biologists, nucleic acid purification column kits are highly redundant in the global molecular market.
  • Serving these demands, TIANGEN designed the groundbreaking research oriented automated extractor: the TGuide S16, empowered by insights of scientist behaviors and expectations, the 12-year experience on automated extractors, and rich supporting reagent kit pools.
  • It has been committed to providing customers with a total solution from sample storage to nucleic acid extraction and detection.

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Thursday, December 1, 2022
Research, Surgery, Medical Devices, Genetics, Biotechnology, Radiology, Health, Science, Oncology, Marketing, EST, Thomas D. Pollard, European Molecular Biology Organization, Laboratory, Lung, Gene, CD320, Brain, ASCB, University of Texas Southwestern Medical Center, University, Cell biology, Prostate, Society, Laboratory developed test, Sirna Therapeutics, LDT, EMBO, Therapy, Cell, Walter, LRP2, BIAF, Biology, Breast, Medical imaging, Research, D.C

Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.

Key Points: 
  • Dr. Elzis recent research that will be presented next week at Cell Bio looks at why it works.
  • bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment.
  • OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells.
  • Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio.

TIANGEN to Roll out a Stunning Automated Solution at Cell Bio 2022

Retrieved on: 
Wednesday, November 30, 2022
European Molecular Biology Organization, Thomas D. Pollard, Head, DC, ASCB, Cell biology, LTD, S16, Society, GM, Booth, EMBO, Research, Cell, Fine chemical, A4

It could be a stunning product for most molecular biologists and cell biologists to learn about.

Key Points: 
  • It could be a stunning product for most molecular biologists and cell biologists to learn about.
  • "Researchers spend lots of their time on the repetitive hands-on experiment, while there hasn't been an optimal automated nucleic acid extraction solution in the global life science market.
  • said Kefei Sun, the GM of TIANGEN, "TIANGEN develops the TGuide S16, that is groundbreaking to this field".
  • It has been committed to providing customers with a total solution from sample storage to nucleic acid extraction and detection.

bioAffinity Technologies Presents its Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

Retrieved on: 
Monday, December 6, 2021
Research, Genetics, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Science, Oncology, Research, EMBO, Lung, ASCB, Prostate, Cancer, LRP2, Technology, Sirna Therapeutics, Brain, Company, Diagnosis, Breast, University, Education, RNA interference, Laboratory, Therapy, COVID-19, Thomas D. Pollard, RNA, CD320, CST, Society, RNA transfection, Â, Medicine, Cell biology, Gene, European Molecular Biology Organization, Vaccine

bioAffinitys discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue, Dr. Elzi said.

Key Points: 
  • bioAffinitys discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue, Dr. Elzi said.
  • bioAffinity Technologies, Inc. ( www.bioaffinitytech.com ) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment.
  • The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells.
  • Research and optimization of its platform technology are conducted in bioAffinity Technologies laboratories at the University of Texas San Antonio.

Molecular Devices launches new environmental control and z-stack acquisition for ImageXpress Pico Automated Cell Imaging System

Retrieved on: 
Monday, December 10, 2018
Molecular Devices, European Molecular Biology Organization, ASCB

SAN JOSE, Calif., Dec. 10, 2018 /PRNewswire-PRWeb/ -- Molecular Devices announced several new features including environmental control and z-stack acquisition for the ImageXpress Pico system, highlighted at ASCB | EMBO 2018, December 8-12 in San Diego, California.

Key Points: 
  • SAN JOSE, Calif., Dec. 10, 2018 /PRNewswire-PRWeb/ -- Molecular Devices announced several new features including environmental control and z-stack acquisition for the ImageXpress Pico system, highlighted at ASCB | EMBO 2018, December 8-12 in San Diego, California.
  • The fully integrated environmental control (EC) option utilizes both humidity and real-time gas monitoring to promote healthy cell growth during long exposure experiments.
  • The system includes CellReporterXpress Automated Imaging and Analysis Software with preconfigured analysis modules including the new double marker expression algorithm for multi-parametric analysis.
  • Molecular Devices delivers a diverse imaging portfolio to allow scientists easier access to protein and cell biology tools to advance their discoveries.